|
Memórias do Instituto Oswaldo Cruz
Fundação Oswaldo Cruz, Fiocruz
ISSN: 1678-8060 EISSN: 1678-8060
Vol. 109, No. 6, 2014, pp. 828-833
|
Bioline Code: oc14122
Full paper language: English
Document type: View Point
Document available free of charge
|
|
Memórias do Instituto Oswaldo Cruz, Vol. 109, No. 6, 2014, pp. 828-833
en |
Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
Zingales, Bianca; Miles, Michael A.; Morases, Carolina B.; Luquestti, Alejandro; Guhl, Felipe; Schijman, Alejandro G. & Ribeiro, Isabela
Abstract
This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discovery and development: selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain selection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, T. cruzi discrete typing units to include in the panel of strains and the number of strains/clones for primary screens and lead compounds. We also consider experimental approaches for in vitro drug assays. The Figure illustrates the current Chagas disease drug-discovery and development landscape.
Keywords
in vitro drug screening; T. cruzi genetic diversity; guidelines
|
|
© Copyright 2014 - Memórias do Instituto Oswaldo Cruz Alternative site location: http://memorias.ioc.fiocruz.br
|
|